Practice Areas

Cabot Law, PC has exceptional depth and experience acting as “transactional” counsel to emerging companies and other technology-based organizations.  The firm represents clients in a wide range of transactional matters, including:

  • Technology platform licensing
  • Pharmaceutical product development and commercialization collaborations
  • Drug target and product candidate alliances
  • FTO licensing
  • University licensing agreements
  • Supply chain contracting and licensing
  • Clinical trial collaborations
  • Funded research partnerships
  • “Day-to-day” contracting for evaluations, material transfer, sponsored research, clinical trials, manufacturing and consulting

Representative Clients

Sarah has been involved in the negotiation of countless complex development and license agreements for pharmaceutical and biotechnology companies for over 20 years for clients such as:

Arvinas Moderna Therapeutics The UCAN Company
AVROBIO Mythic Therapeutics Triton Algae Innovations
Concerto Biosciences, Inc. OncoPep WaveBreak
Enanta Pharmaceuticals Phytolon X-Chem
Ginkgo Bioworks RHEACELL

Other clients in the biotech space include AgaMatrix, who she assisted with major license and supply deals with Sanofi Aventis and Perrigo, and Martek Biosciences Corp (now owned by DSM), who she assisted for many years with multiple major sole-source supply agreements with infant formula manufacturing customers.

Representative Transactions

Sarah represented X-Chem, Inc. in the drafting and negotiation of numerous collaboration and license agreements regarding their DNA-encoded library technology, including their announced transactions with AbbVie, Alexion, AstraZeneca, Bayer Pharma AG, Johnson & Johnson Innovation, MD Anderson Cancer Center, Pfizer Inc and Sanofi.  For further details see:

Sarah represented Arvinas, Inc. in the drafting and negotiation of partnering deals for their novel protein degradation technology platform, including their transactions with Genentech and Merck.  For further details, see:

Sarah represented Acetylon Pharmaceuticals, Inc. in the drafting and negotiation of the collaboration agreement component of their transaction with Celgene Corporation where Celgene invested $100 million to obtain an exclusive option to purchase Acetylon at a price ranging from $500 million to $1.1 billion, contingent on certain milestones. For further details, see:

Sarah represented Enanta Pharmaceuticals, Inc. (Nasdaq:ENTA) in a deal with Novartis Institutes for BioMedical Research regarding Enanta’s NS5A program in the closely watched Hepatitis C space.  Under the terms of the agreement, Enanta received an upfront payment of $34 million and was eligible to receive up to $406 million if certain clinical, regulatory, and commercial milestones were met.  Enanta was also eligible to receive tiered double-digit royalties on worldwide sales of products, and retained co-detail rights in the United States.  For further details, see:

Sarah represented Endo Pharmaceuticals (Nasdaq: ENDP) in the drafting and negotiation of a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in oncology that was announced in January 2011.  Under the expansive deal, the companies would co-develop products coming out of the collaboration and share all development costs.  Orion would have marketing rights in Europe, including Russia, while Endo would retain marketing rights for North America. The companies would pay cross royalties to each other on sales from their respective territories, and would mutually decide the most effective method to maximize product opportunities in rest of world (ROW) territories after and share ROW revenues. Financial terms were not disclosed.  The agreement addressed numerous governance and exclusivity issues, as well as manufacturing issues.  This innovative deal was nominated as a top 5 finalist for the Scrip Award for Best Partnership Alliance for 2011.  For further details, see: